Literature DB >> 25581790

Recognition determinants of broadly neutralizing human antibodies against dengue viruses.

Alexander Rouvinski1, Pablo Guardado-Calvo1, Giovanna Barba-Spaeth1, Stéphane Duquerroy2, Marie-Christine Vaney1, Carlos M Kikuti1, M Erika Navarro Sanchez1, Wanwisa Dejnirattisai3, Wiyada Wongwiwat3, Ahmed Haouz4, Christine Girard-Blanc4, Stéphane Petres4, William E Shepard5, Philippe Desprès6, Fernando Arenzana-Seisdedos7, Philippe Dussart8, Juthathip Mongkolsapaya9, Gavin R Screaton3, Félix A Rey10.   

Abstract

Dengue disease is caused by four different flavivirus serotypes, which infect 390 million people yearly with 25% symptomatic cases and for which no licensed vaccine is available. Recent phase III vaccine trials showed partial protection, and in particular no protection for dengue virus serotype 2 (refs 3, 4). Structural studies so far have characterized only epitopes recognized by serotype-specific human antibodies. We recently isolated human antibodies potently neutralizing all four dengue virus serotypes. Here we describe the X-ray structures of four of these broadly neutralizing antibodies in complex with the envelope glycoprotein E from dengue virus serotype 2, revealing that the recognition determinants are at a serotype-invariant site at the E-dimer interface, including the exposed main chain of the E fusion loop and the two conserved glycan chains. This 'E-dimer-dependent epitope' is also the binding site for the viral glycoprotein prM during virus maturation in the secretory pathway of the infected cell, explaining its conservation across serotypes and highlighting an Achilles' heel of the virus with respect to antibody neutralization. These findings will be instrumental for devising novel immunogens to protect simultaneously against all four serotypes of dengue virus.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25581790     DOI: 10.1038/nature14130

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  48 in total

1.  Electrostatics of nanosystems: application to microtubules and the ribosome.

Authors:  N A Baker; D Sept; S Joseph; M J Holst; J A McCammon
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

2.  Mechanism of dengue virus broad cross-neutralization by a monoclonal antibody.

Authors:  Joseph J B Cockburn; M Erika Navarro Sanchez; Nickolas Fretes; Agathe Urvoas; Isabelle Staropoli; Carlos M Kikuti; Lark L Coffey; Fernando Arenzana Seisdedos; Hugues Bedouelle; Felix A Rey
Journal:  Structure       Date:  2012-01-26       Impact factor: 5.006

3.  Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins.

Authors:  Shee-Mei Lok; Victor Kostyuchenko; Grant E Nybakken; Heather A Holdaway; Anthony J Battisti; Soila Sukupolvi-Petty; Dagmar Sedlak; Daved H Fremont; Paul R Chipman; John T Roehrig; Michael S Diamond; Richard J Kuhn; Michael G Rossmann
Journal:  Nat Struct Mol Biol       Date:  2008-02-10       Impact factor: 15.369

4.  Efficient method for production of high yields of Fab fragments in Drosophila S2 cells.

Authors:  Marija Backovic; Daniel X Johansson; Barbara G Klupp; Thomas C Mettenleiter; Mats A A Persson; Felix A Rey
Journal:  Protein Eng Des Sel       Date:  2010-01-24       Impact factor: 1.650

5.  A new bioinformatics analysis tools framework at EMBL-EBI.

Authors:  Mickael Goujon; Hamish McWilliam; Weizhong Li; Franck Valentin; Silvano Squizzato; Juri Paern; Rodrigo Lopez
Journal:  Nucleic Acids Res       Date:  2010-05-03       Impact factor: 16.971

6.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

7.  Variation of the specificity of the human antibody responses after tick-borne encephalitis virus infection and vaccination.

Authors:  Johanna Jarmer; Jürgen Zlatkovic; Georgios Tsouchnikas; Oksana Vratskikh; Judith Strauß; Judith H Aberle; Vaclav Chmelik; Michael Kundi; Karin Stiasny; Franz X Heinz
Journal:  J Virol       Date:  2014-09-24       Impact factor: 5.103

8.  How good are my data and what is the resolution?

Authors:  Philip R Evans; Garib N Murshudov
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2013-06-13

9.  A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface.

Authors:  Guntur Fibriansah; Joanne L Tan; Scott A Smith; Adamberage R de Alwis; Thiam-Seng Ng; Victor A Kostyuchenko; Kristie D Ibarra; Jiaqi Wang; Eva Harris; Aravinda de Silva; James E Crowe; Shee-Mei Lok
Journal:  EMBO Mol Med       Date:  2014-01-13       Impact factor: 12.137

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  164 in total

1.  Dengue type 1 viruses circulating in humans are highly infectious and poorly neutralized by human antibodies.

Authors:  Rajendra Raut; Kizzmekia S Corbett; Rashika N Tennekoon; Sunil Premawansa; Ananda Wijewickrama; Gayani Premawansa; Piotr Mieczkowski; Claudia Rückert; Gregory D Ebel; Aruna D De Silva; Aravinda M de Silva
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-05       Impact factor: 11.205

2.  Dengue virus: Bumps in the road to therapeutic antibodies.

Authors:  Leslie Goo; Theodore C Pierson
Journal:  Nature       Date:  2015-08-20       Impact factor: 49.962

3.  Characterization of two engineered dimeric Zika virus envelope proteins as immunogens for neutralizing antibody selection and vaccine design.

Authors:  Chunpeng Yang; Fang Zeng; Xinyu Gao; Shaojuan Zhao; Xuan Li; Sheng Liu; Na Li; Chenglin Deng; Bo Zhang; Rui Gong
Journal:  J Biol Chem       Date:  2019-05-28       Impact factor: 5.157

Review 4.  Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials.

Authors:  Aravinda M de Silva; Eva Harris
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

5.  Delineating antibody recognition against Zika virus during natural infection.

Authors:  Lei Yu; Ruoke Wang; Fei Gao; Min Li; Jianying Liu; Jian Wang; Wenxin Hong; Lingzhai Zhao; Yingfen Wen; Chibiao Yin; Hua Wang; Qi Zhang; Yangyang Li; Panpan Zhou; Rudian Zhang; Yang Liu; Xiaoping Tang; Yongjun Guan; Cheng-Feng Qin; Ling Chen; Xuanling Shi; Xia Jin; Gong Cheng; Fuchun Zhang; Linqi Zhang
Journal:  JCI Insight       Date:  2017-06-15

6.  Transposon Mutagenesis of the Zika Virus Genome Highlights Regions Essential for RNA Replication and Restricted for Immune Evasion.

Authors:  Benjamin O Fulton; David Sachs; Megan C Schwarz; Peter Palese; Matthew J Evans
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

Review 7.  Variation, Indispensability, and Masking in the M protein.

Authors:  Partho Ghosh
Journal:  Trends Microbiol       Date:  2017-08-31       Impact factor: 17.079

Review 8.  Vaccination strategies against Zika virus.

Authors:  Estefania Fernandez; Michael S Diamond
Journal:  Curr Opin Virol       Date:  2017-04-19       Impact factor: 7.090

Review 9.  Zika Virus: Immunity and Vaccine Development.

Authors:  Theodore C Pierson; Barney S Graham
Journal:  Cell       Date:  2016-09-29       Impact factor: 41.582

10.  Universal Dengue Vaccine Elicits Neutralizing Antibodies against Strains from All Four Dengue Virus Serotypes.

Authors:  Naoko Uno; Ted M Ross
Journal:  J Virol       Date:  2021-01-28       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.